About Proteolix
Proteolix is a Healthcare company based in San Francisco (United States) founded in 2003, and was acquired by Onyx Pharmaceuticals in October 2009. Targeting protein degradation pathways using proteasome inhibitors to treat cancer. Proteolix has raised $124 million across 2 funding rounds from investors including Westfield Capital, Onyx Pharm and Delphi Ventures. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Proteolix, Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Proteolix was founded in 2003 in San Francisco, United States, within the biotechnology sector focused on oncology. Novel therapeutics are discovered and developed to modulate protein degradation pathways through selective proteasome inhibitors. Operations center on advancing these inhibitors for cancer applications. The lead candidate, carfilzomib (PR-171), is administered intravenously and is under evaluation in clinical trials for safety and efficacy across various cancer types.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website proteolix.com
- Social LinkedIn
- Acquired by Onyx Pharmaceuticals (Oct 2009)
- Legal Name Proteolix, Inc
- Total Equity Funding$124M (USD)
in 2 rounds
- Latest Funding Round$79M (USD), Series C
Sep 2008
- InvestorsWestfield Capital
& 7 more
- Acquired byOnyx Pharmaceuticals
(Oct 2009)
Funding Insights of Proteolix
Proteolix has successfully raised a total of $124M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $79 million completed in September 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $124M
- Total Rounds 2
- Last Round Series C — $79M
- First Round $45M
(May 2006)
- Investors Count 7
All 2 funding rounds of Proteolix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2008 | $79M | Series C | – | Phase4 Ventures | |
| May 2006 | $45M | Series B | – | Delphi Ventures, LVP | – |
8 investors in total: 8 institutional.
Investors in Proteolix
Proteolix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Westfield Capital, Onyx Pharm and Delphi Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
Early-stage healthcare startups are supported with venture capital. | lvpcapital.com | San Ramon, United States | ||
Investments in early and late-stage US companies are made. | vertical-group.com | Basking Ridge, United States | ||
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
VC firm that focuses on early stage investments in the US | usvp.com | Menlo Park, United States | ||
| phase4ventures.com | ||||
Diversified investment management services are provided by Westfield Capital. | 1989 | westfieldcapital.com | Boston, United States | |
Kinase inhibitors for treating various cancers are developed. | 1992 | onyx-pharm.com | San Francisco, United States |
Investor details for Proteolix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proteolix
2 people are tracked at Proteolix (2 in leadership).
| Name | Role | Group |
|---|---|---|
Jinfu Yang | Associate Director | Leadership |
Janice Linver | Vice President | Leadership |
Complete people profiles for Proteolix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Proteolix
4 dated milestones of Proteolix across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Proteolix is founded.
- Funding First funding round of $45.0M.
- Funding Latest funding round, Series C, of $79.0M.
- Exit Acquired by Onyx Pharmaceuticals.
Competitors of Proteolix
Proteolix has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Proteolix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Proteolix (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Proteolix
Complete news archive for Proteolix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proteolix
Proteolix was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Proteolix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Proteolix is a funded company, having raised a total of $124M across 2 funding rounds to date. The company's 1st funding round was a Series B of $45M, raised on May 2006.
Proteolix was founded in 2003 in San Francisco, United States, within the biotechnology sector focused on oncology. Novel therapeutics are discovered and developed to modulate protein degradation pathways through selective proteasome inhibitors. Operations center on advancing these inhibitors for cancer applications. The lead candidate, carfilzomib (PR-171), is administered intravenously and is under evaluation in clinical trials for safety and efficacy across various cancer types.
Proteolix's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Proteolix has 8 investors. Key investors include Westfield Capital, Onyx Pharm, Delphi Ventures, Latterell Venture Partners, and The Vertical Group.
Proteolix operates through Proteolix, Inc.
Yes. Proteolix was acquired by Onyx Pharmaceuticals in October 2009.